Drug Profile


Alternative Names: BAY 102; BAY-1021189; MK-1242

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Merck & Co
  • Class Carbamates; Fluorobenzenes; Heart failure therapies; Peptides; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase I Coronary artery disease

Most Recent Events

  • 11 Nov 2017 Efficacy and adverse events data from the phase I VENICE trial in Coronary artery disease presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 09 Oct 2017 Bayer completes a phase I relative bioavailability and food effect trial in Healthy volunteers in Germany (PO) (NCT03145038)
  • 17 Aug 2017 Bayer initiates enrolment in the VISOR phase I trial for Coronary artery disease in Germany (NCT03255512)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top